Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACES: Multivirus-Specific T-Cells for Refractory Viral Infections
NCT03475212Phase 2Active, not recruiting
- Sponsor
- Pediatric Transplant and Cellular Therapy Consortium
- Start
- Jun 2018
- Primary completion
- Jun 2025
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of HLA-matched multivirus-specific T cells in cytomegalovirus infection (CMV), Epstein-Barr virus infection, adenovirus infection, sponsored by Pediatric Transplant and Cellular Therapy Consortium. Started Jun 2018; status: active, not recruiting.
02
Drugs
HLA-matched multivirus-specific T cells
03
Conditions
cytomegalovirus infection (CMV)Epstein-Barr virus infectionadenovirus infection
Beyond the preview
Go deeper on NCT03475212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03475212.